Dechra Pharmaceuticals posts rise in quarterly revenues

Dechra Pharmaceuticals reported an increase in revenue in the first three months of the year as a rise in Europe sales offset a fall in the US.

Dechra Pharmaceuticals reported an increase in revenue in the first three months of the year as a rise in Europe sales offset a fall in the US.

Group revenue for its third quarter was up 14.6% ahead of last year, according to a trading update Wednesday.

For the nine months ended March 31st, group revenue increased 18.4% compared to the previous year.

A 69.8% jump in quarterly revenues in the European Pharmaceuticals segment drove results. The division climbed 69.7% in the nine-month period.

The acquisition of Eurovet Animal Health last May boosted revenues.

Companion animal products for the nine months to the end of March grew by 11.0% on a like-for-like basis.

Farm animal products, which continued to be affected by a focus on the reduction of antibiotics in Europe, rose by 1.0%. Pet diet jumped 2.0%.

In the US, revenue declined 14.4% in the quarter and were broadly flat in the nine month period, reflecting supply problems from a third party manufacturer. Customer back orders exceeded $1.0m.

Services segment revenues dropped 2.5% in the quarter, due to a weak performance in the UK veterinary market. Poor weather resulted in significantly reduced footfall through veterinary practices.

Revenue for the nine months was, however, was 2.7% ahead of the previous year.

"The strong performance reported in the first half of thefinancial year has been partly offset by a weaker than expected third quarter which was affected by poor weather in Northern Europe and third party supply problems within the US," the company said.

The company said it does not anticipate that the third quarter's performance will materially impact its expectations for the full year as trading picked up in April.

Shares fell 2.25% to 696p at 09:40 Wednesday.

RD

Recommended

How to be better at selling stocks
Investment strategy

How to be better at selling stocks

There is plenty of advice around about buying stocks, but not so much about when you should sell. John Stepek explains the two key things to know abou…
14 Jan 2022
Share tips of the week – 14 January
Share tips

Share tips of the week – 14 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
14 Jan 2022
Fintech: how to profit as technology transforms banking around the world
Share tips

Fintech: how to profit as technology transforms banking around the world

Financial technology – from apps to APIs to the cloud – is rapidly transforming financial services. This will spell doom for some incumbent firms, whi…
14 Jan 2022
Three solid assets to buy for a low interest-rate world
Share tips

Three solid assets to buy for a low interest-rate world

Professional investor Luke Hyde-Smith of the Waverton Real Assets Fund, highlights three alternative investments to diversify your portfolio.
14 Jan 2022

Most Popular

US inflation is at its highest since 1982. Why aren’t markets panicking?
Inflation

US inflation is at its highest since 1982. Why aren’t markets panicking?

US inflation is at 7% – the last time it was this high interest rates were at 14%. But instead of panicking, markets just shrugged. John Stepek explai…
13 Jan 2022
Five unexpected events that could shock the markets in 2022
Stockmarkets

Five unexpected events that could shock the markets in 2022

Forget Covid-19 – it’s the unexpected twists that will rattle markets in 2022, says Matthew Lynn. Here are five possibilities
31 Dec 2021
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022